Skip to main content
OpenTrials
Completed

NCT Number: NCT02638181

The Expression of Matrix Metalloproteinase 13, Tissue Inhibitor of Metalloproteinases 3, and Calcium-sensing Receptor in Human Trabecular Meshwork

This study was to assess the distinct expression of matrix metalloproteinase 13,tissue inhibitor of metalloproteinases 3, and calcium-sensing receptor, in human trabecular meshwork between normal and glaucomatous eyes.The expressions of matrix metalloproteinase 13, tissue inhibitor of metalloproteinases 3 and calcium-sensing receptor in the trabecular meshwork tissues were examined by streptavidin-peroxidase immunohistochemical staining method and western blot, and histological changes of trabecular meshwork were studied by Hematoxylin and Eosin staining.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Open-angle Glaucoma Eye Diseases Glaucoma Glaucoma, Open-Angle Ocular Hypertension

Age range

50 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Tianjin Medical University Eye Hospital

Tianjin, Tianjin Municipality, 300384, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • intraocular pressure greater than 22 mmHg with two or more medications
  • wide anterior chamber angle
  • glaucomatous optic neuropathy (Glaucomatous optic nerve damage was defined as cup-to-disc ratio higher than 0.7 or focal loss of the nerve fiber layer (notch) associated with a consistent glaucomatous visual field defect
  • visual field loss consistent with optic nerve damage and visual fields were performed by using standard automated perimetry

Exclusion criteria

  • the presence of any secondary form of glaucoma including exfoliation syndrome or a history of ocular trauma, etc

Treatment and study plan

trabeculectomy

Procedure

Primary outcomes

  1. the expressions of matrix metalloproteinase 13 and calcium-sensing receptor

    Time frame: one hour after operation

Secondary outcomes

  1. histological changes of trabecular meshwork

    Time frame: one hour after operation

Sponsors and collaborators

Lead sponsor

Lv Yingjuan

Other

Registry information

Official study title

The Expression of Matrix Metalloproteinase 13（MMP13）, Tissue Inhibitor of Metalloproteinases 3（TIMP13）, and Calcium-sensing Receptor（CaSR） in Human Trabecular Meshwork

Important dates

Study start
2013
Primary completion
2015
Study completion
2015
First posted
Dec 23, 2015
Registry last updated
Jan 10, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.